ISRCTN76377555
Completed
未知
Bispectral (BIS) electroencephalogram (EEG) monitored sedation in intensive care unit (ICU) patients. A preliminary randomised controlled trial
Department of Health (UK)0 sites0 target enrollmentSeptember 12, 2003
Overview
- Phase
- 未知
- Intervention
- Not specified
- Conditions
- Not specified
- Sponsor
- Department of Health (UK)
- Status
- Completed
- Last Updated
- 7 years ago
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- •Postoperative cardiac surgery patients who are expected to have an uneventful postoperative recovery.
Exclusion Criteria
- •Not provided at time of registration
Outcomes
Primary Outcomes
Not specified
Similar Trials
Active, not recruiting
Not Applicable
A Phase 2 Randomized, Double Blinded (BMS-562247 and enoxaparin), Active-Controlled (enoxaparin and warfarin), Parallel-Arm, Dose Response Study of the Oral Factor Xa Inhibitor BMS-562247 in Subjects Undergoing Elective Total Knee Replacement SurgeryEUCTR2004-001128-19-DKBristol-Myers Squibb International Corporation1,666
Completed
Not Applicable
2-Year Cerebral Performance Categories According To Initial Rhythm And Resuscitation Time Following In-Hospital Cardiac ArrestIn-Hospital Cardiac ArrestTwo-Year Cerebral Performance CategoriesACTRN12617001370392Konya Numune State Hospital44
Active, not recruiting
Phase 1
A clinical study to assess the efficacy of alpelisib plus fulvestrant in participants with HR-positive, HER2-negative, advanced breast cancer after treatment with a CDK4/6 inhibitor and an aromatase inhibitorHormone receptor positive, HER2-negative advanced breast cancerMedDRA version: 21.1Level: LLTClassification code 10072737Term: Advanced breast cancerSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)Therapeutic area: Diseases [C] - Cancer [C04]EUCTR2021-001966-39-PLovartis Pharma AG234
Active, not recruiting
Phase 1
A clinical study to assess the efficacy of alpelisib plus fulvestrant in participants with HR-positive, HER2-negative, advanced breast cancer after treatment with a CDK4/6 inhibitor and an aromatase inhibitorHormone receptor positive, HER2-negative advanced breast cancerMedDRA version: 21.1Level: LLTClassification code 10072737Term: Advanced breast cancerSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)Therapeutic area: Diseases [C] - Cancer [C04]EUCTR2021-001966-39-DKovartis Pharma AG234
Active, not recruiting
Phase 1
A clinical study to assess the efficacy of alpelisib plus fulvestrant in participants with HR-positive, HER2-negative, advanced breast cancer after treatment with a CDK4/6 inhibitor and an aromatase inhibitorHormone receptor positive, HER2-negative advanced breast cancerMedDRA version: 21.1Level: LLTClassification code 10072737Term: Advanced breast cancerSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)Therapeutic area: Diseases [C] - Cancer [C04]EUCTR2021-001966-39-IEovartis Pharma AG234